Progress in Research and Development of Preventive Vaccines for Children in China

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2024 Jul 18

PMID 39022216

Authors

Xuyang Zheng

Ge Jin

Affiliations

Soon will be listed here.

Abstract

The infant and child stage is an important stage for the continuation and development of human society. The initial years of life have a lasting impact on a child's future. Children under the age of 5 have an immature immune system, especially infants and young children under 6 months of age. At this stage, the population has a low immunity to pathogen infections, making them vulnerable to bacteria and viruses. Vaccination can enhance the immunity of infants and children to specific diseases, reduce the transmission rate of infectious diseases, and promote the development of global public health. This article summarizes the current application status of Rotavirus (RV) vaccine, Hand-foot -mouth disease (HFMD) vaccine, and Pneumococcal Conjugate Vaccine (PCV) in China, as well as the research progress of clinical trial vaccine, laying a foundation for subsequent vaccine development.

References

Zhen S, Li Y, Wang S, Zhang X, Hao Z, Chen Y . Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design. Emerg Microbes Infect. 2015; 4(10):e64. PMC: 4631931. DOI: 10.1038/emi.2015.64. View

Sartori A, de Soarez P, Novaes H . Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil. J Epidemiol Community Health. 2010; 66(3):210-7. DOI: 10.1136/jech.2010.111880. View

Senders S, Klein N, Tamimi N, Thompson A, Baugher G, Trammel J . A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J. 2024; 43(6):596-603. PMC: 11090512. DOI: 10.1097/INF.0000000000004334. View

Blazevic V, Malm M, Arinobu D, Lappalainen S, Vesikari T . Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. Hum Vaccin Immunother. 2015; 12(3):740-8. PMC: 4964741. DOI: 10.1080/21645515.2015.1099772. View

Kim Y, LaFon D, Nahm M . Indirect Effects of Pneumococcal Conjugate Vaccines in National Immunization Programs for Children on Adult Pneumococcal Disease. Infect Chemother. 2016; 48(4):257-266. PMC: 5204004. DOI: 10.3947/ic.2016.48.4.257. View

Chen X, Zhang Y, Mao N, Zhu S, Ji T, Xu W . Intranasal immunization with coxsackievirus A16 virus-like particles confers protection against lethal infection in neonatal mice. Arch Virol. 2019; 164(12):2975-2984. DOI: 10.1007/s00705-019-04418-3. View

Zhang Z, Dong Z, Wang Q, Carr M, Li J, Liu T . Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018; 36(46):7095-7104. DOI: 10.1016/j.vaccine.2018.09.069. View

Li J, Zhang Y, Yang Y, Liang Z, Tian Y, Liu B . Effectiveness of Lanzhou lamb rotavirus vaccine in preventing gastroenteritis among children younger than 5 years of age. Vaccine. 2019; 37(27):3611-3616. DOI: 10.1016/j.vaccine.2019.03.069. View

Chackerian B . Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines. 2007; 6(3):381-90. DOI: 10.1586/14760584.6.3.381. View

10.

Liang Q, Li H, Chang X, Zhang H, Hao H, Ye Q . A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old. Vaccine. 2021; 39(47):6947-6955. DOI: 10.1016/j.vaccine.2021.09.047. View

11.

Alderson M . Status of research and development of pediatric vaccines for Streptococcus pneumoniae. Vaccine. 2016; 34(26):2959-2961. PMC: 4906266. DOI: 10.1016/j.vaccine.2016.03.107. View

12.

Southern J, Andrews N, Sandu P, Sheppard C, Waight P, Fry N . Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England. PLoS One. 2018; 13(5):e0195799. PMC: 5969732. DOI: 10.1371/journal.pone.0195799. View

13.

Sadiq A, Bostan N, Yinda K, Naseem S, Sattar S . Rotavirus: Genetics, pathogenesis and vaccine advances. Rev Med Virol. 2018; 28(6):e2003. DOI: 10.1002/rmv.2003. View

14.

Duan X, Zhang C, Wang X, Ren X, Peng H, Tang X . Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017-2022: a descriptive study. Emerg Microbes Infect. 2022; 11(1):2510-2519. PMC: 9621254. DOI: 10.1080/22221751.2022.2125346. View

15.

Carvalho M, Gill D . Rotavirus vaccine efficacy: current status and areas for improvement. Hum Vaccin Immunother. 2018; 15(6):1237-1250. PMC: 6663136. DOI: 10.1080/21645515.2018.1520583. View

16.

Vesikari T, Matson D, Dennehy P, Van Damme P, Santosham M, Rodriguez Z . Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006; 354(1):23-33. DOI: 10.1056/NEJMoa052664. View

17.

Kim S, Chung D, Song J, Baek J, Thamlikitkul V, Wang H . Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: Emergence of drug-resistant non-vaccine serotypes. Vaccine. 2019; 38(38):6065-6073. DOI: 10.1016/j.vaccine.2019.09.065. View

18.

Plosker G . 13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents. Paediatr Drugs. 2013; 15(5):403-23. DOI: 10.1007/s40272-013-0047-z. View

19.

Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S . Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014; 383(9935):2136-43. PMC: 4532697. DOI: 10.1016/S0140-6736(13)62630-6. View

20.

Baraldo K, Mori E, Bartoloni A, Norelli F, Grandi G, Rappuoli R . Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein. Infect Immun. 2005; 73(9):5835-41. PMC: 1231108. DOI: 10.1128/IAI.73.9.5835-5841.2005. View